Online inquiry

IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11011MR)

This product GTTS-WQ11011MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&CLEC12A gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4; NM_001207010.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 160364
UniProt ID P07766; Q5QGZ9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11011MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6320MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ6427MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CT-P22
GTTS-WQ11511MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ10954MR IVTScrip™ mRNA-Anti-HAVCR2, MBG-453(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MBG-453
GTTS-WQ6619MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ2224MR IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA aVWF81
GTTS-WQ1781MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ9017MR IVTScrip™ mRNA-Anti-MST1R, IMC RON-8(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA IMC RON-8
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW